Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)
Sponsor: Eisai Co., Ltd.
Listed as NCT03059381, this observational or N/A phase trial focuses on Partial Seizures (With or Without Secondary Generalized Seizures) and Primary Generalized Tonic-clonic Seizures and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2022 — Jul 2024 [monthly]
Completed
-
Jun 2021 — Sep 2022 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting
▶ Show 8 earlier versions
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Aug 2019 — May 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Aug 2019 [monthly]
Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Recruiting
-
Sep 2018 — Mar 2019 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .